Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: A double blind, double dummy study

M. Moro, C. Maraschini, P. Toja, A. Masala, S. Alagna, P. P. Rovasio, A. Ginanni, I. Lancranjan, F. Cavagnini

Research output: Contribution to journalArticle

Abstract

The efficacy and tolerabilily of a slow-release preparation of bromocriptine (Parlodel SRO) were compared to those of conventional bromocriptine (Parlodel R) in a double blind, double dummy study of 12 hypcrpro-lactinemic women (plasma PRL 81.3 ± 4.73. ng/ml mean ± SEM). For 2 weeks, the patients received 2.5 mg b.i.d. Parlodel R or 5 mg once daily Parlodel SRO; for the following 2 weeks, the dose of the drugs was doubled. The patients were then treated, in an open study, with 2.5-10 mg daily Parlodel SRO for 6 months. Both preparations caused a prompt and sharp PRL fall. Hormone levels remained inhibited over the whole month of observation with both preparations. Daily PRL profiles were very close with either drug although morning PR1 levels were slightly higher during Parlodel SRO than during Parlodel R administration. Doubling the doses of the two drugs did not result in further significant lowering of PRL values. During the 6-month study with Parlodel SRO, plasma PRL further decreased and normalized in II of 12 patients. Clinical improvement occurred in the majority of cases. Tolerability of Parlodel SRO appeared to be better, though without statistically significant differences, than that of Parlodel R. Side effects were less important with the former compound in their number, severity and duration. In conclusion, thanks to its favourable pharmacological profile. Parlodel SRO appears to be a valuable alternative to regular bromocriptine in the management of hyperprolactinemia.

Original languageEnglish
Pages (from-to)137-141
Number of pages5
JournalHormone Research in Paediatrics
Volume35
Issue number3-4
DOIs
Publication statusPublished - 1991

Fingerprint

Hyperprolactinemia
Bromocriptine
Double-Blind Method
Pharmaceutical Preparations

Keywords

  • Bromocriptine
  • Hyperprolactinemia
  • Slow-release oral bromocriptine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia : A double blind, double dummy study. / Moro, M.; Maraschini, C.; Toja, P.; Masala, A.; Alagna, S.; Rovasio, P. P.; Ginanni, A.; Lancranjan, I.; Cavagnini, F.

In: Hormone Research in Paediatrics, Vol. 35, No. 3-4, 1991, p. 137-141.

Research output: Contribution to journalArticle

Moro, M. ; Maraschini, C. ; Toja, P. ; Masala, A. ; Alagna, S. ; Rovasio, P. P. ; Ginanni, A. ; Lancranjan, I. ; Cavagnini, F. / Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia : A double blind, double dummy study. In: Hormone Research in Paediatrics. 1991 ; Vol. 35, No. 3-4. pp. 137-141.
@article{3a698c0dfd9543bf9e53ba4a629619aa,
title = "Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: A double blind, double dummy study",
abstract = "The efficacy and tolerabilily of a slow-release preparation of bromocriptine (Parlodel SRO) were compared to those of conventional bromocriptine (Parlodel R) in a double blind, double dummy study of 12 hypcrpro-lactinemic women (plasma PRL 81.3 ± 4.73. ng/ml mean ± SEM). For 2 weeks, the patients received 2.5 mg b.i.d. Parlodel R or 5 mg once daily Parlodel SRO; for the following 2 weeks, the dose of the drugs was doubled. The patients were then treated, in an open study, with 2.5-10 mg daily Parlodel SRO for 6 months. Both preparations caused a prompt and sharp PRL fall. Hormone levels remained inhibited over the whole month of observation with both preparations. Daily PRL profiles were very close with either drug although morning PR1 levels were slightly higher during Parlodel SRO than during Parlodel R administration. Doubling the doses of the two drugs did not result in further significant lowering of PRL values. During the 6-month study with Parlodel SRO, plasma PRL further decreased and normalized in II of 12 patients. Clinical improvement occurred in the majority of cases. Tolerability of Parlodel SRO appeared to be better, though without statistically significant differences, than that of Parlodel R. Side effects were less important with the former compound in their number, severity and duration. In conclusion, thanks to its favourable pharmacological profile. Parlodel SRO appears to be a valuable alternative to regular bromocriptine in the management of hyperprolactinemia.",
keywords = "Bromocriptine, Hyperprolactinemia, Slow-release oral bromocriptine",
author = "M. Moro and C. Maraschini and P. Toja and A. Masala and S. Alagna and Rovasio, {P. P.} and A. Ginanni and I. Lancranjan and F. Cavagnini",
year = "1991",
doi = "10.1159/000181889",
language = "English",
volume = "35",
pages = "137--141",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia

T2 - A double blind, double dummy study

AU - Moro, M.

AU - Maraschini, C.

AU - Toja, P.

AU - Masala, A.

AU - Alagna, S.

AU - Rovasio, P. P.

AU - Ginanni, A.

AU - Lancranjan, I.

AU - Cavagnini, F.

PY - 1991

Y1 - 1991

N2 - The efficacy and tolerabilily of a slow-release preparation of bromocriptine (Parlodel SRO) were compared to those of conventional bromocriptine (Parlodel R) in a double blind, double dummy study of 12 hypcrpro-lactinemic women (plasma PRL 81.3 ± 4.73. ng/ml mean ± SEM). For 2 weeks, the patients received 2.5 mg b.i.d. Parlodel R or 5 mg once daily Parlodel SRO; for the following 2 weeks, the dose of the drugs was doubled. The patients were then treated, in an open study, with 2.5-10 mg daily Parlodel SRO for 6 months. Both preparations caused a prompt and sharp PRL fall. Hormone levels remained inhibited over the whole month of observation with both preparations. Daily PRL profiles were very close with either drug although morning PR1 levels were slightly higher during Parlodel SRO than during Parlodel R administration. Doubling the doses of the two drugs did not result in further significant lowering of PRL values. During the 6-month study with Parlodel SRO, plasma PRL further decreased and normalized in II of 12 patients. Clinical improvement occurred in the majority of cases. Tolerability of Parlodel SRO appeared to be better, though without statistically significant differences, than that of Parlodel R. Side effects were less important with the former compound in their number, severity and duration. In conclusion, thanks to its favourable pharmacological profile. Parlodel SRO appears to be a valuable alternative to regular bromocriptine in the management of hyperprolactinemia.

AB - The efficacy and tolerabilily of a slow-release preparation of bromocriptine (Parlodel SRO) were compared to those of conventional bromocriptine (Parlodel R) in a double blind, double dummy study of 12 hypcrpro-lactinemic women (plasma PRL 81.3 ± 4.73. ng/ml mean ± SEM). For 2 weeks, the patients received 2.5 mg b.i.d. Parlodel R or 5 mg once daily Parlodel SRO; for the following 2 weeks, the dose of the drugs was doubled. The patients were then treated, in an open study, with 2.5-10 mg daily Parlodel SRO for 6 months. Both preparations caused a prompt and sharp PRL fall. Hormone levels remained inhibited over the whole month of observation with both preparations. Daily PRL profiles were very close with either drug although morning PR1 levels were slightly higher during Parlodel SRO than during Parlodel R administration. Doubling the doses of the two drugs did not result in further significant lowering of PRL values. During the 6-month study with Parlodel SRO, plasma PRL further decreased and normalized in II of 12 patients. Clinical improvement occurred in the majority of cases. Tolerability of Parlodel SRO appeared to be better, though without statistically significant differences, than that of Parlodel R. Side effects were less important with the former compound in their number, severity and duration. In conclusion, thanks to its favourable pharmacological profile. Parlodel SRO appears to be a valuable alternative to regular bromocriptine in the management of hyperprolactinemia.

KW - Bromocriptine

KW - Hyperprolactinemia

KW - Slow-release oral bromocriptine

UR - http://www.scopus.com/inward/record.url?scp=0026076535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026076535&partnerID=8YFLogxK

U2 - 10.1159/000181889

DO - 10.1159/000181889

M3 - Article

C2 - 1806467

AN - SCOPUS:0026076535

VL - 35

SP - 137

EP - 141

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 3-4

ER -